All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results VERU-111, 2022 0.30 [0.14; 0.64]
0.30 [0.14 ; 0.64 ] VERU-111, 2022 1 0% 150 NA not evaluable death D28detailed results CAN-COVID, 2020 0.67 [0.30; 1.50]
Silva, 2021 0.46 [0.03; 8.02]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
0.62 [0.43 ; 0.89 ] CAN-COVID, 2020, Silva, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 3 0% 1,682 moderate not evaluable deathsdetailed results CAN-COVID, 2020 0.67 [0.30; 1.50]
Kirti, 2021 0.12 [0.01; 2.36]
Libster, 2020 0.50 [0.09; 2.71]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
Lopes MIF, 2020 1.06 [0.02; 56.61]
NCT04342650, 2020 0.95 [0.02; 48.42]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
Rocco, 2020 1.02 [0.02; 51.70]
SAVE-MORE, 2021 0.45 [0.20; 0.99]
Shenoy S, 2021 1.32 [0.58; 2.99]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
0.66 [0.51 ; 0.85 ] CAN-COVID, 2020, Kirti, 2021, Libster, 2020, LIVE-AIR (Temesgen), 2021, Lopes MIF, 2020, NCT04342650, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rocco, 2020, SAVE-MORE, 2021, Shenoy S, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 11 0% 4,071 moderate low deaths (time to event analysis only)detailed results LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
0.70 [0.40 ; 1.21 ] LIVE-AIR (Temesgen), 2021 1 0% 479 NA not evaluable clinical deteriorationdetailed results Libster, 2020 0.52 [0.29; 0.94]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.53 [0.15; 1.95]
Rocco, 2020 1.02 [0.29; 3.58]
SAVE-MORE, 2021 0.36 [0.26; 0.50]
0.43 [0.31 ; 0.60 ] Libster, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rocco, 2020, SAVE-MORE, 2021 4 12% 677 low not evaluable clinical improvementdetailed results CAN-COVID, 2020 1.39 [0.76; 2.54]
Rocco, 2020 0.81 [0.52; 1.27]
1.02 [0.61 ; 1.71 ] CAN-COVID, 2020, Rocco, 2020 2 49% 838 serious not evaluable clinical improvement (7-day)detailed results Kirti, 2021 0.90 [0.77; 1.06]
Rocco, 2020 0.81 [0.52; 1.27]
0.89 [0.77 ; 1.03 ] Kirti, 2021, Rocco, 2020 2 0% 504 moderate not evaluable clinical improvement (time to event analysis only)detailed results Shenoy S, 2021 0.99 [0.77; 1.28]
Shinkai, 2021 1.40 [0.91; 2.15]
1.13 [0.81 ; 1.56 ] Shenoy S, 2021, Shinkai, 2021 2 46% 936 serious not evaluable death or ventilationdetailed results LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
0.65 [0.50 ; 0.86 ] LIVE-AIR (Temesgen), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 2 0% 1,197 moderate not evaluable hospital dischargedetailed results Kirti, 2021 1.20 [0.73; 1.98]
RIVET-COV (Mohan) (12mg and 24mg), 2021 2.31 [0.66; 8.04]
Shenoy S, 2021 1.06 [0.85; 1.32]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
1.21 [0.98 ; 1.50 ] Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021, Shenoy S, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 4 17% 2,214 serious not evaluable hospitalizationdetailed results Holubar M, 2021 0.12 [0.01; 2.26]
Jagannathan, 2020 1.00 [0.14; 7.34]
0.46 [0.06 ; 3.45 ] Holubar M, 2021, Jagannathan, 2020 2 28% 269 low not evaluable mechanical ventilationdetailed results Kirti, 2021 0.20 [0.00; 8.69]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
SAVE-MORE, 2021 0.47 [0.03; 7.48]
0.38 [0.05 ; 2.67 ] Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021, SAVE-MORE, 2021 3 0% 858 moderate not evaluable viral clearance detailed results Chaccour, 2020 0.92 [0.77; 1.09]
Holubar M, 2021 0.76 [0.48; 1.20]
Jagannathan, 2020 0.81 [0.56; 1.18]
Rastogi, 2020 6.33 [1.54; 26.00]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39]
0.94 [0.70 ; 1.27 ] Chaccour, 2020, Holubar M, 2021, Jagannathan, 2020, Rastogi, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021 5 53% 447 low not evaluable viral clearance (time to event analysis only)detailed results Ahmed, 2020 4.10 [1.12; 14.99]
Holubar M, 2021 0.76 [0.48; 1.20]
Jagannathan, 2020 0.81 [0.56; 1.18]
1.00 [0.56 ; 1.78 ] Ahmed, 2020, Holubar M, 2021, Jagannathan, 2020 3 66% 341 low not evaluable viral clearance by day 14detailed results Ahmed, 2020 4.10 [1.12; 14.99]
4.10 [1.12 ; 14.99 ] Ahmed, 2020 1 0% 72 NA not evaluable viral clearance by day 7detailed results Chaccour, 2020 0.92 [0.77; 1.09]
Kirti, 2021 0.80 [0.43; 1.50]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39]
0.92 [0.78 ; 1.08 ] Chaccour, 2020, Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021 3 0% 250 low not evaluable ICU admissiondetailed results Kirti, 2021 0.90 [0.30; 2.70]
Libster, 2020 0.33 [0.07; 1.58]
Rocco, 2020 4.11 [0.18; 91.83]
0.75 [0.28 ; 1.99 ] Kirti, 2021, Libster, 2020, Rocco, 2020 3 14% 664 moderate not evaluable recoverydetailed results Crippa (CANDIDATE), 2021 0.54 [0.15; 1.94]
0.54 [0.15 ; 1.94 ] Crippa (CANDIDATE), 2021 1 0% 91 NA not evaluable serious adverse eventsdetailed results CAN-COVID, 2020 0.73 [0.45; 1.19]
Jagannathan, 2020 1.00 [0.14; 7.34]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
Shinkai, 2021 2.80 [0.14; 56.95]
0.77 [0.48 ; 1.21 ] CAN-COVID, 2020, Jagannathan, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Shinkai, 2021 4 0% 876 moderate not evaluable adverse eventsdetailed results Chaccour, 2020 1.00 [0.20; 5.07]
Holubar M, 2021 2.07 [0.89; 4.83]
Jagannathan, 2020 1.33 [0.63; 2.78]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.25 [0.45; 3.47]
Shinkai, 2021 19.54 [7.77; 49.11]
2.41 [0.81 ; 7.14 ] Chaccour, 2020, Holubar M, 2021, Jagannathan, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Shinkai, 2021 5 84% 598 moderate not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-29 05:33 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 90
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290
